CANF supply chain intelligence for Can-Fite BioPharma Ltd.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
Can-Fite BioPharma Ltd. (CANF) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| OPHTHALIX | OPHTHALIX | 90% | In addition, immediately prior to the Merger, OphthaliX sold on an “as is” basis to us all the ordinary shares of Eye-Fite |
| ABT | Abbott Laboratories | 72% | Reciprocal relationship from ABT graph: Reciprocal relationship from CANF graph: Reciprocal relationship from ABT graph: Reciprocal relationship from CANF graph: Reciprocal relationship from ABT grap… |
| ABT | Abbott Laboratories | 72% | ient, or API, through a leading Chinese contract research organization, or CRO. The relevant suppliers of our drug products are compliant with both current Good Manufacturing Practices, or cGMP, and … |
| JNJ | Johnson & Johnson | 72% | Reciprocal relationship from JNJ graph: Reciprocal relationship from CANF graph: ient, or API, through a leading Chinese contract research organization, or CRO. The relevant suppliers of our drug pro… |
| JNJ | Johnson & Johnson | 72% | ient, or API, through a leading Chinese contract research organization, or CRO. The relevant suppliers of our drug products are compliant with both current Good Manufacturing Practices, or cGMP, and … |
| NVO | Novo Nordisk A/S | 72% | ient, or API, through a leading Chinese contract research organization, or CRO. The relevant suppliers of our drug products are compliant with both current Good Manufacturing Practices, or cGMP, and … |
| NVO | Novo Nordisk A/S | 72% | Reciprocal relationship from NVO graph: Reciprocal relationship from CANF graph: Reciprocal relationship from NVO graph: Reciprocal relationship from CANF graph: Reciprocal relationship from NVO grap… |
| ORANY | ORANY | 72% | nd clinical trials. Additionally, as a result of these failures, we may also be unable to obtain additional financing. 61 Governmental authorities in all major markets require that a new pharmaceutic… |
| ORANY | ORANY | 72% | Reciprocal relationship from ORANY graph: Reciprocal relationship from CANF graph: nd clinical trials. Additionally, as a result of these failures, we may also be unable to obtain additional financin… |
| SNYNF | Sanofi | 72% | Reciprocal relationship from SNYNF graph: Reciprocal relationship from CANF graph: ient, or API, through a leading Chinese contract research organization, or CRO. The relevant suppliers of our drug p… |
| SNYNF | Sanofi | 72% | ient, or API, through a leading Chinese contract research organization, or CRO. The relevant suppliers of our drug products are compliant with both current Good Manufacturing Practices, or cGMP, and … |
| XTLB | XTL Biopharmaceuticals Ltd. | 72% | Reciprocal relationship from XTLB graph: Reciprocal relationship from CANF graph: Reciprocal relationship from XTLB graph: Reciprocal relationship from CANF graph: Reciprocal relationship from XTLB g… |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| CHONG-KUN-DANG-PHARMACEUTICALS-CORP | CHONG-KUN-DANG-PHARMACEUTICALS-CORP | 85% | obligation amounted to $ 1,581 and $ 1,986 , respectively and are presented under deferred revenues. During the year ended December 31, 2025, the Company recognized revenues in the amount of $ 405 wh… |
| EWOPHARMA-AG | EWOPHARMA-AG | 85% | obligation amounted to $ 1,581 and $ 1,986 , respectively and are presented under deferred revenues. During the year ended December 31, 2025, the Company recognized revenues in the amount of $ 405 wh… |
| EYE-FITE-LTD | EYE-FITE-LTD | 85% | we granted an exclusive license for the use of our Piclidenoson drug candidate in the ophthalmic field, or the License Agreement, to Eye-Fite Ltd., an Israel limited company, or Eye-Fite |
| GEBRO-HOLDING-GMBH | GEBRO-HOLDING-GMBH | 85% | obligation amounted to $ 1,581 and $ 1,986 , respectively and are presented under deferred revenues. During the year ended December 31, 2025, the Company recognized revenues in the amount of $ 405 wh… |
| NVO | Novo Nordisk A/S | 72% | Reciprocal relationship from NVO graph: Reciprocal relationship from CANF graph: ne. Manufacturing We are currently manufacturing our API through a leading CRO. The relevant suppliers of our drug pro… |
| NVO | Novo Nordisk A/S | 72% | ne. Manufacturing We are currently manufacturing our API through a leading CRO. The relevant suppliers of our drug products are compliant with both current Good Manufacturing Practices, or cGMP, and … |
| ORANY | ORANY | 72% | Reciprocal relationship from ORANY graph: Reciprocal relationship from CANF graph: Reciprocal relationship from ORANY graph: Reciprocal relationship from CANF graph: Reciprocal relationship from ORAN… |
| ORANY | ORANY | 72% | tes, the Public Health Service Act and the Federal Food, Drug, and Cosmetic Act (FDCA), as amended, and the regulations promulgated thereunder, and other federal and state statutes and regulations go… |
| AFFILIATION-DR-KIM-PAPP-HEAD-PROBITY-MEDICAL-RES | AFFILIATION-DR-KIM-PAPP-HEAD-PROBITY-MEDICAL-RES | 62% | ne. Manufacturing We are currently manufacturing our API through a leading CRO. The relevant suppliers of our drug products are compliant with both current Good Manufacturing Practices, or cGMP, and … |
| CV-THERAPEUTICS-INC | CV-THERAPEUTICS-INC | 62% | elopment of, facilities to manufacture a sufficient supply of our product candidates. We do not have the resources, facilities or experience to manufacture our product candidates for commercial purpo… |
| KYONGBO-PHARM-CO-LTD | KYONGBO-PHARM-CO-LTD | 62% | for example, increased rebates for drugs subject to the Medicaid Drug Rebate Program, extension of Medicaid rebates to Medicaid managed care plans, mandatory discounts for certain Medicare Part D ben… |
| NORDISK-ROCHE-GSK-SAGIMET-BIOSCIENCES-INVENTIVA- | NORDISK-ROCHE-GSK-SAGIMET-BIOSCIENCES-INVENTIVA- | 62% | elopment of, facilities to manufacture a sufficient supply of our product candidates. We do not have the resources, facilities or experience to manufacture our product candidates for commercial purpo… |
| NYSE-AMERICAN-COMPANY | NYSE-AMERICAN-COMPANY | 62% | be unable to protect the intellectual property rights of the third parties from whom we license certain of our intellectual property or with whom we have entered into other strategic relationships. ●… |
| PFE | Pfizer Inc. | 62% | Reciprocal relationship from PFE graph: Reciprocal relationship from CANF graph: Reciprocal relationship from PFE graph: Reciprocal relationship from CANF graph: Reciprocal relationship from PFE grap… |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| CANF-DEBT | Debt stack $71,000 | 90% | Market cache reports total debt of $71,000. |
| CANF-DEBT-8466 | Warrants outstanding: 60000000 | 90% | xbrl warrant detail from xbrl 2024-08-08. |
| Holder | Name | Confidence | Evidence |
|---|---|---|---|
| CANF-OWNER-MORGAN-STANLEY | MORGAN STANLEY | 90% | 13F overlay lists MORGAN STANLEY as top holder; 1 tracked holders. |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| LLY | Eli Lilly and Company | 100.00 | 2 | |
| NVO | Novo Nordisk A/S | 100.00 | 1 | ['customer', 'supplier'] |
| HIMS | Hims & Hers Health, Inc. | 100.00 | 2 | |
| JNJ | Johnson & Johnson | 100.00 | 1 | ['supplier'] |
| SDGR | Schrödinger, Inc. | 100.00 | 2 | |
| CRBP | Corbus Pharmaceuticals Holdings, Inc. | 100.00 | 2 | |
| ORANY | ORANGE | 100.00 | 1 | ['customer', 'supplier'] |
| EVAX | Evaxion A/S | 100.00 | 2 | |
| NONOF | Novo Nordisk A/S | 100.00 | 2 | |
| ASND | Ascendis Pharma A/S | 100.00 | 2 | |
| XTLB | XTL Biopharmaceuticals Ltd. | 100.00 | 1 | ['supplier'] |
| IPHA | Innate Pharma S.A. | 100.00 | 2 | |
| ALNY | Alnylam Pharmaceuticals, Inc. | 100.00 | 2 | |
| AYTU | Aytu BioPharma, Inc. | 50.00 | 2 | |
| ARQQW | Arqit Quantum Inc. | 50.00 | 2 | |
| ASBPW | Aspire Biopharma Holdings, Inc. | 50.00 | 2 | |
| CPRX | Catalyst Pharmaceuticals, Inc. | 50.00 | 2 | |
| AMZE | Amaze Holdings, Inc. | 50.00 | 2 | |
| BLTE | Belite Bio, Inc | 50.00 | 2 | |
| BCDRF | Banco Santander, S.A. | 50.00 | 2 |